$AMGN Company News Charting a Fed-induced market

New Post Public Reply Private Reply Replies (0) Message Board

Oct 9, 2014 at 11:24 AM

$AMGN Company News

Charting a Fed-induced market whipsaw 3 min ago - Michael Ashbaugh
Dow industrials venture to uncharted territory 9:53 a.m. Sept. 17, 2014 - Michael Ashbaugh
Nasdaq breaks out, reaches less-charted territory 12:05 p.m. Aug. 19, 2014 - Michael Ashbaugh
Nasdaq breaks out, reaches less-charted territory 11:56 a.m. Aug. 19, 2014 - Michael Ashbaugh
Nasdaq breaks out, reaches less-charted territory 11:44 a.m. Aug. 19, 2014 - Michael Ashbaugh
Berkshire Hathaway tops $200,000; Cisco drops on results 12:19 p.m. Aug. 14, 2014 - Angela Johnson
Cisco volatile after hours in wake of earnings 5:03 p.m. Aug. 13, 2014 - Sue Chang
Amgen recalls syringes of anemia drug Aranesp 4:55 p.m. Aug. 13, 2014 - Russ Britt
CORRECT: Amgen shares fall after-hours on disappointing trial data 4:34 p.m. Aug. 13, 2014 - Tomi Kilgore
U.S. stocks rally; Dow snaps 4-session losing streak 4:14 p.m. Aug. 4, 2014 - Barbara Kollmeyer
Mobileye rises for second day; Michael Kors falls 1:23 p.m. Aug. 4, 2014 - Angela Johnson
Amgen shares rally 2.7% to top S&P 500 9:30 a.m. Aug. 4, 2014 - Sue Chang
Amgen reports successful late-stage trial of cancer treatment 8:34 a.m. Aug. 4, 2014 - Joshua Jamerson
Amgen reports positive trial of multiple myeloma treatment 7:49 a.m. Aug. 4, 2014 - Ciara Linnane
Tesla Shares Weaken in After Hours 8:13 p.m. July 31, 2014 - MarketWatch
Small health companies see large gains on a big earnings day 5:34 p.m. July 30, 2014 - blogs.marketwatch.com
Twitter, U.S. Steel soar; Buffalo Wild Wings are burned 4:26 p.m. July 30, 2014 - MarketWatch
Edwards, Hospira rise as health-care companies see strong earnings 1:08 p.m. July 30, 2014 - blogs.marketwatch.com
Amgen shares hit record on cost-cutting plans 10:50 a.m. July 30, 2014 - blogs.marketwatch.com
Twitter shines; Fed statement and GDP due today 4:38 a.m. July 30, 2014 - MarketWatch

Portfolio Changes For The Third Quarter 2014 9:14 a.m. Today - Seeking Alpha
Illumina Pads Gene Sequencing Lead With Pharma Deals 3:04 p.m. Oct. 8, 2014 - Investors Business Daily
3 Stocks Reiterated As A Buy: CELG, AIG, AMGN 1:59 p.m. Oct. 8, 2014 - TheStreet.com
Amgen's Data on Evolocumab Published in The Lancet - Analyst Blog 11:20 a.m. Oct. 8, 2014 - Zacks.com
Phase 3 successful for Amgen's adalimumab biosimilar 9:47 a.m. Oct. 8, 2014 - Seeking Alpha
Dollar Daze 4:11 p.m. Oct. 7, 2014 - Barrons.com
Comparing America's 2 Largest Biotechnology Companies 1:57 p.m. Oct. 7, 2014 - Seeking Alpha
Kinder Morgan Energy Partners Edges Berkshire Hathaway For 'Best Value Bond Trade' 2:38 a.m. Oct. 7, 2014 - Seeking Alpha
Some Old Stocks Still Have Young Legs 5:47 p.m. Oct. 6, 2014 - Investors Business Daily
Ligand Earns Milestone Payment on EU Approval of Noxafil - Analyst Blog 1:00 p.m. Oct. 2, 2014 - Zacks.com
Stock Market News for October 02, 2014 - Market News 10:10 a.m. Oct. 2, 2014 - Zacks.com
Evolocumab successful in two Phase 3 studies 8:15 a.m. Oct. 2, 2014 - Seeking Alpha
Amgen, Inc. Showing Strong Performance Despite Low Beta 11:06 a.m. Sept. 30, 2014 - benzinga.com
Celgene Has A Very Bright Future Ahead 4:26 p.m. Sept. 29, 2014 - Seeking Alpha
AMGN, ACT And GILD, Pushing Drugs Industry Downward 1:03 p.m. Sept. 29, 2014 - TheStreet.com
3 Likely Biotech Buyout Candidates 7:48 a.m. Sept. 29, 2014 - 247WallSt.com
'Tax Inversions' Are Tip Of An Iceberg That Already Cost The U.S. Treasury Hundreds Of Billions 2:50 a.m. Sept. 28, 2014 - Seeking Alpha
Celldex (CLDX) Up on Pilot Study Initiation on CDX-301 - Analyst Blog 5:20 p.m. Sept. 26, 2014 - Zacks.com
'Fast Money' Recap: How to Trade After the Market's Drop 5:00 a.m. Sept. 26, 2014 - TheStreet.com
BioMarin (BMRN) Faces Threat of Genericization for Kuvan - Analyst Blog 6:24 p.m. Sept. 25, 2014 - Zacks.com

Amgen Announces Positive Top-Line Results From Phase 3 Study Evaluating The Efficacy And Safety Of Biosimilar Candidate ABP 501 Compared With Adalimumab In Patients With Moderate-To-Severe Plaque Psoriasis 9:15 a.m. Oct. 8, 2014 - PR Newswire - PRF
Global Biosimilar Market Outlook 2018 8:09 p.m. Oct. 1, 2014 - PR Newswire - PRF
The Lancet Publishes Two Phase 3 Studies Showing Cholesterol-Lowering Medication Evolocumab Significantly Reduced LDL Cholesterol In Patients With Serious Genetic Disorders That Cause High Cholesterol 7:01 p.m. Oct. 1, 2014 - PR Newswire - PRF
Earnings Release Schedules, Data Presentation, Regulatory Approvals, and Strategic Collaboration - Research Reports on Covidien, Biogen, Amgen, Agios and Baxter 8:55 a.m. Oct. 1, 2014 - PR Newswire - PRF
Bococizumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 3:55 p.m. Sept. 29, 2014 - PR Newswire - PRF
Amgen to Host Summary Webcast of Kyprolis® (carfilzomib) for Injection Data Presented at The European Society for Medical Oncology (ESMO) 2014 Congress 5:02 p.m. Sept. 24, 2014 - PR Newswire - PRF
Q Therapeutics Expands Board of Directors With Appointment of Dr. Hunter Jackson as Independent Member 4:22 p.m. Sept. 23, 2014 - Marketwire
Regulatory Approval, Presentation of Data, Appointment, Clinical Study Results, and Increase in Quarterly Dividend - Research Reports on Johnson & Johnson, Merck, Medtronic, Amgen and Covidien 9:05 a.m. Sept. 23, 2014 - PR Newswire - PRF
Amgen Submits Biologics License Application for Investigational BiTE® Immunotherapy Blinatumomab 9:00 a.m. Sept. 22, 2014 - PR Newswire - PRF
New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 4:00 p.m. Sept. 15, 2014 - PR Newswire - PRF
Event Schedules, Survey Findings, Regulatory Filings, and Market Activity - Research Reports on Amgen, Biogen Idec, Salix, Covidien and Shire 8:50 a.m. Sept. 15, 2014 - PR Newswire - PRF
Amgen Presents Analyses Of Phase 3 Ivabradine Data For The Treatment Of Chronic Heart Failure 9:00 p.m. Sept. 14, 2014 - PR Newswire - PRF
Reporting Bias in Clinical Trials: What's the current status? 10:30 a.m. Sept. 10, 2014 - PR Newswire - PRF
Amgen Announces 23 Abstracts To Be Presented At The American Society for Bone and Mineral Research 2014 Annual Meeting 9:15 a.m. Sept. 10, 2014 - PR Newswire - PRF
Critical Alerts For Alcoa, Twitter, General Mills, SunEdison and Amgen Released By InvestorsObserver 9:31 a.m. Sept. 9, 2014 - PR Newswire - PRF
Zenith Epigenetics Strengthens its Management Team with Key Appointments 5:34 p.m. Sept. 8, 2014 - PR Newswire - PRF
Fitch Affirms Amgen's IDR at 'BBB'; Outlook Remains Negative 3:13 p.m. Sept. 8, 2014 - BusinessWire - BZX
The Psoriatic Arthritis Market Will Reach More than $3.5 Billion in 2023, Owing to Continued Uptake of Biologics and Penetration of Premium-Priced Orals 10:00 a.m. Sept. 8, 2014 - PR Newswire - PRF
Amgen To Present At The Morgan Stanley Global Healthcare Conference 4:04 p.m. Sept. 5, 2014 - PR Newswire - PRF
Upcoming Presentations, Technical Update, Study Results, and Marketing Authorization Application - Research Reports on Novartis, InterMune, Johnson & Johnson, Amgen and Merck 9:00 a.m. Sept. 5, 2014 - PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Legacy of Professor Raymond Yukna: A Laser Pioneer

End of an Era in Periodontology For those of us who have a stake in the world of dental technology, today hangs heavy. We talk about innovators, pioneers, and game-changers all the time, but Dr. Raymond A. Yukna wasn't just another name on that list - he was the list. The guy practically wrote the book on modern periodontal therapy. With his passing, we're not just saying...

Excellence Award Celebrates Medicilon-Revolution Partnership

Breaking the 'Undruggable' Myth Out there in the trenches of drug discovery, this Medicilon and Revolution Medicines partnership has been stirring up some waves. Now, I ain't talking about your daily Wall Street hubbub, but a three-year grind that's led to something seriously noteworthy: turning the so-called 'undruggable' KRAS target into a real game-changer. Pan-KRAS...

Blue Moon Metals Scraps Major Acquisition Plan

Blue Moon Metals' Acquisition Detour Blue Moon Metals Inc. (NASDAQ: BMM), a name that's been stirring up chatter for its ambitious mining ventures, has waved goodbye to its planned acquisition of 33 U.S.-based tungsten and antimony projects. This move, announced on October 30, 2026, may have caught some investors off guard. The acquisition sounded like a good fit: a...

Texas Auto Insurance: Know Your Limits and Risks

Unpacking the Texas Auto Insurance Puzzle Ah, Texas. Land of vast highways and, apparently, some rather eyebrow-raising auto insurance complexities. Teri Cappadona from the Sapp Insurance Agency took to HelloNation to lay down the lowdown. If you're not up to speed, you might be blindsiding your bank account. We've all grumbled at those insurance bills, but understanding...

MadaLuxe Snags DUXIANA in North American Expansion

MadaLuxe's Bold Step into Luxury Sleep Here's a twist in the luxury game: MadaLuxe Group has grabbed the reins of DUXIANA's North American distribution business. If you haven't run into this iconic Swedish brand yet, it's been peddling high-end beds for a good century. Yep, 100 years of Swedish craftsmanship now in the pocket of MadaLuxe. They didn't spill any beans on...

Sen. Collins Lauded for Transformative Kidney Care

Steering Towards Innovation in Kidney Care In the world of political accolades, real achievements sometimes get buried beneath the pomp. But when the largest kidney patient group in the nation—AAKP, decides to honor Senator Susan M. Collins, it's not just another pat on the back. This one's got substance galore. Collins, a heavyweight on the U.S. Senate Committee on...

Okta Joins S&P 500 Amidst Major Index Shuffles

Okta Leaps to S&P 500: A Power Play You blink for a second, and boom, Okta's sitting at the big kids' table—the S&P 500. You know how rare that move is? It’s like snagging an invite to the party everyone wants to attend. Swapping out Kenvue Inc. (NYSE: KVUE), which Kimberly-Clark (NASD: KMB) is scooping up, Okta's maneuver signifies a hefty endorsement of its growth...

Visionary Animator Julian Glander to Speak at RMCAD

Art Meets Animation: Glander's Inspiring Visit In the offbeat, winding world of creativity, Julian Glander's name rings some serious bells. This Pittsburgh-based powerhouse, known for his whimsical animations and illustrations, is heading to Rocky Mountain College of Art + Design (RMCAD) for the 2026/2027 Friction Series. It's happening November 10—pencil that in...

Alignment Healthcare Faces Investigation Over Alleged Fraud

Rough Waters at Alignment Healthcare Not every day we hear about a company sinking its own ship over bookkeeping shenanigans, but here we are. Alignment Healthcare, sitting on Nasdaq under ticker ALHC, is facing the kind of scrutiny that sends shivers down a boardroom's spine. Yeah, Kahn Swick & Foti—those big hitters in securities litigation—have launched an...

Hot Chili Sizzles with La Verde Copper Drill Gains

Big Copper Moves at La Verde: What's New? Look, when it comes to copper, Hot Chili Limited is throwing down some serious markers. You see, their La Verde project is turning into a hotbed of activity thanks to their latest drilling revelations. They've managed to confirm a second porphyry center, which is like finding another gold mine, except with copper. This essentially...